It’s easy to make the switch.

UpCard-CA1 is now available in 32 mL and 96 mL bottles with 1 mL and 10 mL syringes, respectively.

UpCard-CA1 is conditionally approved by the FDA for use with pimobendan, spironolactone, and an angiotensin converting enzyme (ACE) inhibitor for the management of pulmonary edema in dogs with congestive heart failure caused by myxomatous mitral valve disease (MMVD).^1,2

Full prescribing information.

UpCard-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-577. It is a violation of Federal law to use this product other than as directed in the labeling.

IMPORTANT SAFETY INFORMATION: UpCard-CA1 is for use in dogs only. Do not administer to dogs with renal failure, anuria, severe dehydration, hypovolemia, or hypotension. Do not administer UpCard-CA1 concomitantly with other loop diuretics or to dogs with hypersensitivity to the active substance, torsemide, or to any of the excipients. UpCard-CA1 should be used only in stable dogs with congestive heart failure caused by MMVD which has been diagnosed by means of a comprehensive physical and cardiac examination. This drug has not been evaluated in dogs used for breeding, pregnant, or lactating bitches. The most common side effects seen in dogs with CHF due to MMVD while taking UpCard-CA1 are cough, dyspnea, pulmonary edema, and cardiac arrest. Adverse reactions not related to disease progression in dogs receiving UpCard-CA1 include polyuria and polydipsia, renal insufficiency, increased BUN and serum creatinine, urinary incontinence, hypokalemia, hypochloremia, hypercalcemia, hypomagnesemia, diarrhea, vomiting, and inappetence.  For full prescribing information, visit vetoquinolusa.com/upcard-ca1-info.

References

¹UpCard-CA1 Freedom of Information survey.
²UpCard-CA1 Product label.